For adults with chronic liver disease (CLD) who have thrombocytopenia and are scheduled to undergo a procedure.

LIFTING PLATELETS FOR ADULTS WITH CHRONIC LIVER DISEASE1

Help raise your patients’ platelet counts in just 5 days with Doptelet.1

Doptelet Platelet Characters in the Woods

About Doptelet for chronic liver disease

In 2 randomized, double-blind, placebo-controlled studies (N=435)1:

5 DAYS

With just 5 daily doses, Doptelet can help raise platelet counts.1*

50,000 OR More

Significantly more patients taking Doptelet reached a platelet count ≥50,000/μL compared to placebo.1†

2X

On average, patients taking Doptelet nearly doubled their platelet count in time for a procedure.1‡

Doptelet works with the body to increase platelet counts1

Doptelet helps provide added protection during and after the procedure1§

Significantly reduced the need for platelet transfusions or rescue procedures for bleeding up to 7 days post procedure.1§

Scroll left and right to view the full chart.

Use the Doptelet Scheduling Calendar to plan your patient’s dosing start date.

How Doptelet works

Doptelet works with your body to increase platelet production in chronic liver disease.1

  • Doptelet is an oral thrombopoietin receptor agonist (TPO-RA). Doptelet is an oral TPO-RA that mimics TPO in the body.1,3
  • Thrombopoietin (TPO) is a hormone produced in the liver that acts by binding to hematopoietic stem cell receptors in the bone marrow3,4
  • When bound to these cell receptors, TPO activates the JAK-STAT signaling pathway, resulting in stem cell differentiation to megakaryocytes, leading to the production of platelets3,4
  • Doptelet acts by binding to the same receptors as the endogenous TPO, albeit at a different binding site, ultimately activating the JAK-STAT pathway, which increases platelet production3,4
  • Doptelet does not block native TPO; it allows for an additive effect to endogenous platelet production1

Watch Video

Mechanism of action
*A measured increase in platelet counts was observed in Doptelet treatment groups over time beginning on Day 4 post-dose, that peaked on days 10–13, decreased 7 days post-procedure, and then returned to near baseline values by Day 35.1 
†Secondary endpoint: On procedure day (10 to 13 days after starting Doptelet 40 mg or 60 mg once daily for 5 days), a greater proportion of patients achieved platelet counts of >50×109/L compared to placebo (P<0.0001; N=435).1
‡Secondary endpoint: Doptelet-treated patients had a significantly greater mean increase in platelet counts from baseline to the day of procedure compared to placebo (P<0.0001; N=435).1
§The primary endpoint was the proportion of patients who did not require a platelet transfusion or any rescue procedure for bleeding after randomization and up to 7 days following an elective procedure.1
IIIn pooled analysis of ADAPT-1 and ADAPT-2 (N=277).1

JAK-STAT=Janus kinase-signal transducer and activator of transcription.

Where would you like to go next?

I'm interested in the clinical profile of Doptelet

I'm considering Doptelet for my adult patient with chronic liver disease

VIEW EFFICACY 

I’m reviewing how to dose Doptelet

SEE DOSING 

I’m looking for access and financial support information

I’m starting a patient on Doptelet and looking for patient and financial support

EXPLORE ACCESS 

  1. DOPTELET (avatrombopag) [prescribing information]. Morrisville, NC: AkaRx, Inc; 2025.
  2. Terrault N, Chen Y, Izumi N, et al. Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology. 2018;155(3):718.
  3. Kuter DJ. The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag. Blood Rev. 2022;53:100909.
  4. Zufferey A, Kapur R, Semple JW. Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP). J Clin Med. 2017;6(2):16.